Form 4: Third Rock Ventures Reduces Tango Therapeutics Stake

Third Rock Ventures, a 10% owner and director, reported sales of Tango Therapeutics common stock totaling 729,365 shares in early September 2025 under a Rule 10b5-1 plan.

Summary

• Third Rock Ventures IV, L.P., a 10% owner and director of Tango Therapeutics, Inc. (TNGX), reported sales of common stock.
• On September 5, 2025, 642,906 shares were sold at a price of $7.00 per share.
• On September 8, 2025, an additional 86,459 shares were sold at a weighted average price of $7.0395 per share, with prices ranging from $7.00 to $7.14.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan.
• Following these sales, Third Rock Ventures IV, L.P. beneficially owns 14,727,516 shares of Tango Therapeutics common stock.

Sentiment

Score: 4

Explanation: The sale by a significant institutional investor is generally a negative signal, but the execution under a 10b5-1 plan mitigates the immediate concern of new negative information. It suggests a planned portfolio adjustment rather than an urgent exit.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1(c) plan, which suggests the transactions were not based on new, material non-public information.

Negatives

• A significant institutional investor and 10% owner reduced its stake in the company by a total of 729,365 shares.
• The sales occurred at prices around $7.00 per share, which could be interpreted as a lack of conviction for significant near-term price appreciation by the selling entity.

Future Outlook

NA

Industry Context

This filing reflects a routine insider transaction by a venture capital firm that is a significant shareholder in a biotechnology company. Such sales by institutional investors are common as funds mature or rebalance portfolios, especially when executed under a Rule 10b5-1 plan, which pre-schedules trades to avoid insider trading concerns.

Related Party Transactions

• Third Rock Ventures IV, L.P., a 10% owner and director, sold shares of Tango Therapeutics common stock.

Stakeholder Impact

• Shareholders: May interpret the sales as a negative signal, potentially leading to downward pressure on the stock price, although the 10b5-1 plan mitigates this to some extent.
• Company Management: The sales by a significant investor could be a point of discussion, but the pre-planned nature reduces the implication of a lack of confidence in current operations.

Key Dates

Recommendation

While the sale by a 10% owner and director could be seen as a negative signal, the execution under a Rule 10b5-1 plan suggests a pre-planned portfolio adjustment rather than a reaction to new, adverse information. Investors should monitor future filings and company performance, but this specific transaction does not warrant an immediate 'sell' given its pre-scheduled nature. A 'hold' recommendation is appropriate to observe further developments.

Keywords

Tango Therapeutics, TNGX, Third Rock Ventures, Insider Sales, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Investment Fund